TNF and inflammatory bowel disease: New biological agents, such as anti-tumor necrosis factor-α (TNFα) (infliximab, adalimumab, golimumab), anti-integrin α4β7 (vedolizumab), anti-IL12/23 (ustekinumab) monoclonal antibodies and, most recently, small molecules (Janus kinase [JAK] inhibitors), have improved IBD management [8,9,10].